학술논문
Fluoxetine and Sertraline Potently Neutralize the Replication of Distinct SARS-CoV-2 Variants.
Document Type
Article
Author
Thümmler, Laura; Beckmann, Nadine; Sehl, Carolin; Soddemann, Matthias; Braß, Peer; Bormann, Maren; Brochhagen, Leonie; Elsner, Carina; Hoertel, Nicolas; Cougoule, Céline; Ciesek, Sandra; Widera, Marek; Dittmer, Ulf; Lindemann, Monika; Horn, Peter A.; Witzke, Oliver; Kadow, Stephanie; Kamler, Markus; Gulbins, Erich; Becker, Katrin Anne
Source
Subject
*SARS-CoV-2
*SERTRALINE
*FLUOXETINE
*SARS-CoV-2 Omicron variant
*CLINICAL trials
*
*
*
*
Language
ISSN
1999-4915
Abstract
The pandemic caused by SARS-CoV-2 is still a major health problem. Newly emerging variants and long-COVID-19 represent a challenge for the global health system. In particular, individuals in developing countries with insufficient health care need easily accessible, affordable and effective treatments of COVID-19. Previous studies have demonstrated the efficacy of functional inhibitors of acid sphingomyelinase against infections with various viruses, including early variants of SARS-CoV-2. This work investigated whether the acid sphingomyelinase inhibitors fluoxetine and sertraline, usually used as antidepressant molecules in clinical practice, can inhibit the replication of the former and recently emerged SARS-CoV-2 variants in vitro. Fluoxetine and sertraline potently inhibited the infection with pseudotyped virus-like particles and SARS-CoV-2 variants D614G, alpha, delta, omicron BA.1 and omicron BA.5. These results highlight fluoxetine and sertraline as priority candidates for large-scale phase 3 clinical trials at different stages of SARS-CoV-2 infections, either alone or in combination with other medications. [ABSTRACT FROM AUTHOR]